tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

GERN Stock Latest News

Geron Amends Term Loan Facility to Extend Draw Deadlines
Company AnnouncementsGeron Amends Term Loan Facility to Extend Draw Deadlines
5d ago
8K
GERN
Geron Announces Strategic Restructuring Plan
PremiumCompany Announcements
Geron Announces Strategic Restructuring Plan
25d ago
8K
GERN
Midday Fly By: Disney invests $1B in OpenAI, Oracle reports mixed Q2
PremiumThe Fly
Midday Fly By: Disney invests $1B in OpenAI, Oracle reports mixed Q2
1M ago
F
U
Geron’s Restructuring Efforts and Strategic Focus Lead to Hold Rating Amidst Revenue Stagnation
PremiumRatings
Geron’s Restructuring Efforts and Strategic Focus Lead to Hold Rating Amidst Revenue Stagnation
1M ago
GERN
Geron announces restructuring plan, one-third workforce reduction
PremiumThe Fly
Geron announces restructuring plan, one-third workforce reduction
1M ago
GERN
Cautious Hold Rating for Geron’s Imetelstat Amid Incremental Clinical Trial Updates
PremiumRatingsCautious Hold Rating for Geron’s Imetelstat Amid Incremental Clinical Trial Updates
1M ago
GERN
Geron announces new data presented at ASH 2025
Premium
The Fly
Geron announces new data presented at ASH 2025
1M ago
GERN
Unusually active option classes on open November 14th
Premium
The Fly
Unusually active option classes on open November 14th
2M ago
EU
TZA
Geron Corporation’s Q3 2025 Financial Performance and Strategic Progress
PremiumCompany Announcements
Geron Corporation’s Q3 2025 Financial Performance and Strategic Progress
2M ago
GERN
Geron Corporation’s Earnings Call: Mixed Sentiments and Future Prospects
PremiumCompany Announcements
Geron Corporation’s Earnings Call: Mixed Sentiments and Future Prospects
2M ago
GERN
Buy Rating Maintained for Geron Despite Rytelo Sales Dip, Strong Financial Position Supports Strategic Shift
PremiumRatings
Buy Rating Maintained for Geron Despite Rytelo Sales Dip, Strong Financial Position Supports Strategic Shift
2M ago
GERN
Strategic Initiatives and Market Expansion Drive Buy Rating for Geron
PremiumRatings
Strategic Initiatives and Market Expansion Drive Buy Rating for Geron
2M ago
GERN
Geron reports Q3 EPS (3c), consensus (4c)
PremiumThe FlyGeron reports Q3 EPS (3c), consensus (4c)
2M ago
GERN
Geron sees FY25 operating expenses $250M-$260M
Premium
The Fly
Geron sees FY25 operating expenses $250M-$260M
2M ago
GERN
GERN Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
GERN Earnings this Week: How Will it Perform?
2M ago
GERN
Geron Announces Executive Leadership Transitions
PremiumCompany Announcements
Geron Announces Executive Leadership Transitions
3M ago
8K
GERN
Geron COO Andrew Grethlein, CCO Jim Ziegler to depart
PremiumThe Fly
Geron COO Andrew Grethlein, CCO Jim Ziegler to depart
3M ago
GERN
Geron Corporation’s Phase 3 Study on Imetelstat: A Potential Game-Changer for Myelofibrosis Treatment
PremiumCompany Announcements
Geron Corporation’s Phase 3 Study on Imetelstat: A Potential Game-Changer for Myelofibrosis Treatment
5M ago
GERN
Geron Corporation’s Phase 3 Study on Imetelstat: A Potential Game-Changer for Myelofibrosis Treatment
PremiumCompany Announcements
Geron Corporation’s Phase 3 Study on Imetelstat: A Potential Game-Changer for Myelofibrosis Treatment
5M ago
GERN
Geron Corporation’s Phase 3 Study: A Potential Game-Changer for Myelofibrosis Treatment
PremiumCompany AnnouncementsGeron Corporation’s Phase 3 Study: A Potential Game-Changer for Myelofibrosis Treatment
5M ago
GERN
Geron Inc.: Buy Rating Affirmed Amid Promising Leadership and Growth Prospects
Premium
Ratings
Geron Inc.: Buy Rating Affirmed Amid Promising Leadership and Growth Prospects
5M ago
GERN
Positive Momentum and Strategic Leadership Drive Buy Rating for Geron Amid Growing Demand for Rytelo
Premium
Ratings
Positive Momentum and Strategic Leadership Drive Buy Rating for Geron Amid Growing Demand for Rytelo
5M ago
GERN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >